CORAL Study Brings Positive News for Adults With Depression


Coadministration of zuranolone with a standard antidepressant yields positive outcomes.

Sagar Parikh, MD, FRCPC, shares news about the CORAL Study examining zuranolone treatment in patients with major depressive disorder, which demonstrated a rapid and statistically significant reduction in depressive symptoms at day 3 and over the 2-week treatment period.

To read more about this study, see: Improving Depression Symptoms: Study Meets Endpoints.

Dr Parikh is a professor of Depression and Clinical Neuroscience, and Psychiatry Sciences, at the University of Michigan.

Related Videos
Experts on MDD.
Experts on MDD.
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
© 2023 MJH Life Sciences

All rights reserved.